Navigation path

Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

4,7,10,13,16,19-docosahexaenoic acid

EU orphan designation number: EU/3/06/412   
Active ingredient: 4,7,10,13,16,19-docosahexaenoic acid
Indication: Treatment of retinitis pigmentosa
Sponsor: Natac Pharma S.L.
C/ Faraday 7, 28049 Madrid, España

   Public summary of scientific opinion    

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
12/12/2006 Centralised Orphan - Designation EMEA/OD/057/06 (2006)5377 of 03/11/2006
01/09/2011 Centralised Orphan - Transfer of orphan designation EMEA/OD/057/06/T/01 (2011)6288 of 30/08/2011
03/06/2013 Centralised Orphan - Transfer of orphan designation EMEA/OD/057/06/T/02 (2013)2931 of 15/05/2013